Objective To explore a feasible simplified premedication protocol for preventing hypersensitivity reactions to taxanes. Methods The electronic medical record system was used to search for data from 49 patients with advanced gastric cancer who received paclitaxel liposome treatment for the first time in the gastroenterology department of Shanghai Changhai Hospital from 2021-06-01 to 2024-06-30, including premedication protocols, allergic reactions, and other adverse reactions. Results Among 31 patients, the premedication regimen included oral dexamethasone 9 mg at 12 h and 6 h prior to liposomal paclitaxel, plus oral loratadine 10 mg and oral ranitidine 150 mg at 12 h prior to treatment. Among 18 patients, the regimen included oral dexamethasone 9 mg at 12 h and 6 h prior to treatment, and oral loratadine 10 mg at 12 h prior to treatment. None of the patients experienced allergic reactions. The incidence of other adverse reactions did not differ significantly between the two groups（P>0.05）. Conclusion Based on literature and practice, a dual simplified premedication protocol of oral corticosteroids（GC）combined with oral H1 receptor blockers（H1RA）was proposed, which provided a new idea for doctors. Further clinical studies are needed to verify its effectiveness.

Objective To explore a feasible simplified premedication protocol for preventing hypersensitivity reactions to taxanes. Methods The electronic medical record system was used to search for data from 49 patients with advanced gastric cancer who received paclitaxel liposome treatment for the first time in the gastroenterology department of Shanghai Changhai Hospital from 2021-06-01 to 2024-06-30, including premedication protocols, allergic reactions, and other adverse reactions. Results Among 31 patients, the premedication regimen included oral dexamethasone 9 mg at 12 h and 6 h prior to liposomal paclitaxel, plus oral loratadine 10 mg and oral ranitidine 150 mg at 12 h prior to treatment. Among 18 patients, the regimen included oral dexamethasone 9 mg at 12 h and 6 h prior to treatment, and oral loratadine 10 mg at 12 h prior to treatment. None of the patients experienced allergic reactions. The incidence of other adverse reactions did not differ significantly between the two groups（P>0.05）. Conclusion Based on literature and practice, a dual simplified premedication protocol of oral corticosteroids（GC）combined with oral H1 receptor blockers（H1RA）was proposed, which provided a new idea for doctors. Further clinical studies are needed to verify its effectiveness.

Objective To investigate the disease characteristics, potential drug interactions, and key points of pharmaceutical care in patients with inflammatory bowel disease and atrial fibrillation, so as to provide a reference for rational clinical medication use. Methods Through involvement in the pharmaceutical care of a patient with inflammatory bowel disease and atrial fibrillation, and by reviewing relevant literature, the clinical pharmacist assessed the rationality of the medication regimen, proposed medication reconciliation recommendations, and assisted the multidisciplinary team in optimizing the treatment plan. Results Following the intervention, the patient's inflammatory bowel disease-related symptoms were improved significantly, atrial fibrillation was effectively controlled, and no significant adverse drug reactions were observed. Conclusion There exists a complex bidirectional interaction between inflammatory bowel disease and atrial fibrillation in terms of pathological mechanisms and pharmacotherapy. Through individualized medication reconciliation and multidisciplinary pharmaceutical care, safe and effective long-term management of those patients can be achieved.

Nonspecific peripheral T-cell lymphoma (PTCL-NOS) combined with pure red cell aplasia (PRCA) is reported by only few in China. This article described a patient with PTCL-NOS who presented with severe anemia as the initial symptom, accompanied by multiple lymphadenopathy. Laboratory tests confirmed decreased red blood cell count and reticulocyte proportion, markedly reduced bone marrow red blood cell proliferation, and markedly increased proportion of bone marrow CD3 +CD8 + T lymphocytes. On lymph node pathology examination, immunohistochemistry was consistent with PTCL-NOS, with positive TCRβ gene rearrangement. First-line chemotherapy with four courses of ECHOP regimen led to significant reductions in lymph node size, partial remission on whole-body computed tomography evaluation, normalization of hemoglobin and bone marrow hematopoietic erythroid proliferation, and absence of CD3 +CD8 + T lymphocytes in bone marrow. Currently, the patient remains to have good prognosis with maintenance oral lenalidomide.

Nonspecific peripheral T-cell lymphoma (PTCL-NOS) combined with pure red cell aplasia (PRCA) is reported by only few in China. This article described a patient with PTCL-NOS who presented with severe anemia as the initial symptom, accompanied by multiple lymphadenopathy. Laboratory tests confirmed decreased red blood cell count and reticulocyte proportion, markedly reduced bone marrow red blood cell proliferation, and markedly increased proportion of bone marrow CD3 +CD8 + T lymphocytes. On lymph node pathology examination, immunohistochemistry was consistent with PTCL-NOS, with positive TCRβ gene rearrangement. First-line chemotherapy with four courses of ECHOP regimen led to significant reductions in lymph node size, partial remission on whole-body computed tomography evaluation, normalization of hemoglobin and bone marrow hematopoietic erythroid proliferation, and absence of CD3 +CD8 + T lymphocytes in bone marrow. Currently, the patient remains to have good prognosis with maintenance oral lenalidomide.